SMTL ID : 8uak.1

Crystal structure of the catalytic domain of human PKC alpha (D463N, V568I, S657E) in complex with Darovasertib (NVP-LXS196) at 2.82-A resolution

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.82 Å

Oligo State

monomer

Ligands

1 x W39: (6M)-3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide(Non-covalent)

W39.1: 17 residues within 4Å: Chain A: L.27, G.28, F.32, V.35, A.48, E.69, T.83, M.99, E.100, Y.101, V.102, D.106, D.149, N.150, M.152, A.162, D.163 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:L.27, A:F.32, A:F.32, A:D.163 Hydrogen bonds: A:E.100, A:V.102

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Visser, M. et al., Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma. J.Med.Chem. (2024)

Release Date

2024-01-24

Peptides

Protein kinase C alpha type: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Protein kinase C alpha type

Related Entries With Identical Sequence